Last updated on March 2019

Study Evaluating Safety Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer


Brief description of study

A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer

Detailed Study Description

This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 administered as a short term intravenous (IV) infusion in subjects with small cell lung cancer. AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE) targeting delta-like protein 3 (DLL3)

Clinical Study Identifier: NCT03319940

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Kashiwa-shi, Japan
3.0miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.